New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
10:23 EDTAES, NPSP, PRTA, SRPT, SA, S, TMUS, ULTI, VZ, MDVN, HCLP, T, CF, CTIC, CTL, CBPO, CSOD, FQVLF, FTR, WINOn The Fly: Analyst Initiation Summary
AES Corp. (AES) initiated with an Equal Weight at Morgan Stanley... AT&T (T) initiated with a Market Perform at Bernstein... CF Industries (CF) initiated with a Neutral at UBS... Cell Therapeutics (CTIC) initiated with a Buy at Ladenburg... CenturyLink (CTL) initiated with a Market Perform at Bernstein... China Biologic (CBPO) initiated with a Buy at Jefferies... Cornerstone OnDemand (CSOD) initiated with an Outperform at FBR Capital... First Quantum Minerals (FQVLF) initiated with an Underweight at HSBC... Frontier Communications (FTR) initiated with a Market Perform at Bernstein... Hi-Crush Partners (HCLP) initiated with an Outperform at Cowen... Medivation (MDVN) initiated with a Buy at Stifel... NPS Pharmaceuticals (NPSP) coverage resumed with a Buy at Janney Capital... Prothena (PRTA) initiated with a Buy at Ladenburg... Sarepta (SRPT) initiated with a Buy at Roth Capital... Seabridge Gold (SA) initiated with a Speculative Buy at Canaccord... Sprint (S) initiated with a Market Perform at Bernstein... T-Mobile (TMUS)initiated with a Market Perform at Bernstein... Ultimate Software (ULTI) initiated with a Market Perform at FBR Capital... Verizon (VZ) initiated with an Outperform at Bernstein... Windstream (WIN) initiated with an Outperform at Bernstein.
News For AES;T;CF;CTIC;CTL;CBPO;CSOD;FQVLF;FTR;HCLP;MDVN;NPSP;PRTA;SRPT;SA;S;TMUS;ULTI;VZ;WIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
October 20, 2014
08:07 EDTTMUST-Mobile coverage resumed with an Overweight at Morgan Stanley
Subscribe for More Information
07:17 EDTVZVerizon weekly volatility elevated into Q3 and outlook
Verizon October weekly call option implied volatility is at 25, November and January is at 16; compared to its 26-week average of 15 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 21.
07:15 EDTTAT&T weekly volatility elevated into Q3 and outlook
Subscribe for More Information
06:56 EDTNPSPShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 19, 2014
16:44 EDTSRPTEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
14:39 EDTSSprint job cuts include 452 at Kansas headquarters, Bloomberg says
According to a filing yesterday with the Kansas Department of Commerce, the job cuts at Sprint that were announced earlier this month, will include 452 positions in Overland Park, Kansas, where the company is headquartered, says Bloomberg. Reference Link
13:39 EDTSRPTCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTSRPTBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTSRPTSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
09:17 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:31 EDTCBPOChina Biologic receives approval for commercial manufacturing of prothrombin
Subscribe for More Information
05:10 EDTCFYara announces termination of merger discussions with CF Industries
Yara International ASA (YARIY) and CF Industries (CF) have terminated their discussions regarding a potential merger of equals transaction. Torgeir Kvidal, president and CEO of Yara International ASA stated, "This has been a constructive process, with solid work by both parties. We were able to identify significant structural and operational synergies, but in the end it became clear that we would not be able to agree on terms that would be acceptable to all stakeholders."
October 16, 2014
18:36 EDTSRPTOn The Fly: After Hours Movers
Subscribe for More Information
18:16 EDTSRPTSarepta up 10.6% following publication of Ebola phase 1 clinical study
17:55 EDTCFCF Industries announces termination of merger talks with Yara International
CF Industries (CF) announced that the company and Yara International (YARIY) have terminated their discussions regarding a potential merger of equals transaction. “I want to thank the management team and Board of Directors of Yara International for their cooperation and professionalism throughout our discussions,” stated Tony Will, president and CEO, CF Industries. “Although we identified very significant operational and structural synergies, we were ultimately unable to agree on terms of a transaction that met the requirements of all our respective shareholders.” Will continued, “CF Industries has a strong stand-alone business plan and we are confident in the material increase in our cash flow generation as our capacity expansion projects come on-stream as scheduled. We remain fully committed to driving shareholder value creation by investing in high return projects while returning excess cash to stockholders through dividends and a substantial share repurchase program.”
16:43 EDTHCLPHi-Crush Partners increases quarterly dividend 9% to 6.25c
Subscribe for More Information
16:13 EDTSRPTSarepta announces publication of Ebola, Marburg Phase I clinical study results
Sarepta Therapeutics announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers, which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta’s advanced and proprietary PMOplus chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288.
14:13 EDTCFU.S farmers use less fertilizer this autumn as crop prices fade, Reuters says
Subscribe for More Information
08:29 EDTTAT&T sees 359K customers seek refunds for 'cramming' charges, Time reports
Subscribe for More Information
08:12 EDTSASeabridge Gold reports additional drilling results at KSM Project in Canada
Seabridge Gold announced additional results from this year's drill program at its 100% owned KSM Project in northwestern British Columbia, Canada. Results from the Iron Cap Lower Zone continue to outline a major new gold-copper discovery beneath Iron Cap, one of KSM's four large porphyry deposits. Data from eight new holes and seven holes announced previously are expected to support an initial resource estimate for the Iron Cap Lower Zone scheduled for 1Q15.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use